Last updated: June 1, 2026
Olezarsen Sodium Suppliers: Who Manufactures API, Formulations, and Clinical/Commercial Drug Product
Olezarsen sodium is a research-stage antisense oligonucleotide (ASO) with supply typically constrained by (1) specialized ASO active ingredient manufacturing, (2) conjugate/fill-finish capabilities for oligonucleotide drug product, and (3) contractual exclusivity tied to the sponsor’s development and distribution model. No supplier roster can be stated from the provided information.
Which companies supply olezarsen sodium API and drug substance?
No complete, verifiable supplier list can be produced from the information available here.
What types of API suppliers handle olezarsen sodium (ASO) manufacturing?
- ASO oligonucleotide chemistry and scale-up (protected solid-phase synthesis, deprotection, purification)
- Analytical release testing (identity, purity, oligonucleotide length distribution, mass, sequence verification)
- Controlled environment manufacturing and documentation suited to oligonucleotide CMC packages
Who supplies olezarsen sodium drug product (formulation, fill-finish, labeling)?
No complete, verifiable supplier list can be produced from the information available here.
What CMC capabilities are required to formulate olezarsen sodium?
- Oligonucleotide-compatible buffers and excipients
- Sterile drug product manufacturing (if the route requires sterile administration)
- Oligonucleotide stability handling (freeze-thaw, viscosity control, container compatibility)
- GMP fill-finish and packaging under sponsor quality agreements
What contracts exist for olezarsen sodium manufacturing or CDMO work?
No contract or named-CDMO sourcing information can be stated from the information available here.
Is olezarsen sodium supplied through a single-source model or multiple CDMOs?
No sourcing model can be stated from the information available here.
How does olezarsen sodium supplier selection differ by clinical phase vs commercial?
No phase-by-phase sourcing information can be stated from the information available here.
Which supply-chain risks affect olezarsen sodium availability?
No olezarsen-specific supplier risk assessment can be produced from the information available here.
Typical ASO supply constraints for this class
- Limited CDMOs with ASO oligonucleotide scale and analytics depth
- Batch release complexity driven by oligo purity and sequence control
- Analytical method transfer and qualification timelines
- Stability and shipping constraints for cold-chain oligonucleotide products
What is olezarsen sodium’s FDA status and how does that map to supplier visibility?
No FDA status and no supplier visibility mapping can be produced from the information available here.
Key Takeaways
- Olezarsen sodium supplier identification requires sponsor/CDMO/labeler and Orange Book/CMC visibility, but no supplier roster is provided in the information available here.
- No defensible list of companies supplying olezarsen sodium API or drug product can be stated without sourced, verifiable identifiers.
FAQs
- How do I identify olezarsen sodium suppliers for API vs drug product?
- Do ASO sponsors typically use the same CDMO across clinical phases for manufacturing?
- Where are oligonucleotide supplier names usually disclosed (labeler, CMC, filings)?
- What CDMO qualifications matter most for antisense oligonucleotide products?
- How can a change in CDMO impact olezarsen sodium regulatory comparability?
References
- (No sources were provided.)
